Has Uzoma Osuchukwu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,435 in general payments to Uzoma Osuchukwu, MD across 196 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Uzoma Osuchukwu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Uzoma Osuchukwu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Uzoma Osuchukwu, MD

Child & Adolescent Psychiatry · North Las Vegas, NVNPI 1063760411

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 27.0% of the total.

$4,435in general payments, 2019–2025

Across 196 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
Johnson & Johnson$863
Alkermes, Inc.$539
Otsuka America Pharmaceutical, Inc.$469
E.r. Squibb & Sons, L.L.C.$279
Corium, LLC$174
plus $915 from 13 others

What the payments were for

Food & beverage$4,35598%
Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	54	$1,196
Johnson & Johnson	36	$863
Alkermes, Inc.	20	$539
Otsuka America Pharmaceutical, Inc.	19	$469
E.r. Squibb & Sons, L.L.C.	12	$279
Corium, LLC	8	$174
Lundbeck LLC	9	$167
AbbVie	8	$157
Vanda Pharmaceuticals Inc.	3	$115
Sunovion Pharmaceuticals Inc.	6	$91
Bausch Health US, LLC	4	$89
Ironshore Pharmaceuticals Inc.	5	$84
Neurocrine Biosciences, Inc.	3	$55
Supernus Pharmaceuticals, Inc.	3	$44
Avion Pharmaceuticals	2	$31
Axsome Therapeutics, Inc.	1	$28
Tempus AI, Inc	1	$26
Vertical Pharmaceuticals, LLC	1	$16
Shire North American Group Inc	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,435 in reported general payments places this provider in the 80th percentile of 26 child & adolescent psychiatry providers in Nevada.

See all child & adolescent psychiatry providers in Nevada →

Medicare billing

Part B allowed, 2024

$23,031

Medicare patients

Services billed

237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Vilazodone Hcl	18	$2,227
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	43	$1,539
Fluvoxamine Maleate ErFluvoxamine Maleate	12	$1,009
Clonazepam	30	$594
Bupropion XlBupropion Hcl	54	$504
Buspirone Hcl	27	$486
Quetiapine Fumarate	36	$454
Hydroxyzine Pamoate	16	$342
Mirtazapine	14	$335
Divalproex Sodium ErDivalproex Sodium	12	$274
Lorazepam	33	$265
Trazodone Hcl	36	$260
Topiramate	21	$225
Risperidone	13	$201
Propranolol Hcl	19	$165

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in North Las Vegas

Jerome NwokikeNorth Las Vegas$5K
Ann ChildressLas Vegas$1.4M
Joan CarapucciLas Vegas$7K
Emmanuel NwapaLas Vegas$7K
Sonia RuppStateline$1K
Rosa BellotaLas Vegas$1K
Brian GradyReno$978
Chau PhamHenderson$958
Michelle Fontenelle-GilmerLas Vegas$904
Corydon ClarkLas Vegas$777

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →